The Competition and Markets Authority (CMA) has provisionally cleared the completed acquisition by Alliance Medical of assets of the IBA Molecular business used to produce a radioactive tracer for cancer diagnosis.The two companies supply Fluorodeoxyglucose 18F (FDG-18), a radioactive tracer used in PET-CT scans that is purchased by hospitals and other providers of such scans….
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
